E
Appili Therapeutics Inc.
APLIF
$0.029
$0.003815.08%
E
Sell
11/10/2023Downgrade
Appili Therapeutics Inc. (APLIF) was downgraded to E+ from D- on 11/10/2023 due to a decline in the volatility index.
Appili Therapeutics Inc. (APLIF) was downgraded to E+ from D- on 11/10/2023 due to a decline in the volatility index.
D
Sell
10/25/2023Upgraded
Appili Therapeutics Inc. (APLIF) was upgraded to D- from E+ on 10/25/2023 due to an increase in the volatility index.
Appili Therapeutics Inc. (APLIF) was upgraded to D- from E+ on 10/25/2023 due to an increase in the volatility index.
E
Sell
10/6/2023Downgrade
Appili Therapeutics Inc. (APLIF) was downgraded to E+ from D- on 10/6/2023 due to a decline in the volatility index.
Appili Therapeutics Inc. (APLIF) was downgraded to E+ from D- on 10/6/2023 due to a decline in the volatility index.
D
Sell
9/21/2023Upgraded
Appili Therapeutics Inc. (APLIF) was upgraded to D- from E+ on 9/21/2023 due to an increase in the total return index and volatility index.
Appili Therapeutics Inc. (APLIF) was upgraded to D- from E+ on 9/21/2023 due to an increase in the total return index and volatility index.
E
Sell
3/14/2023Downgrade
Appili Therapeutics Inc. (APLIF) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
Appili Therapeutics Inc. (APLIF) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
3/6/2023Upgraded
Appili Therapeutics Inc. (APLIF) was upgraded to D from D- on 3/6/2023 due to an increase in the volatility index and valuation index.
Appili Therapeutics Inc. (APLIF) was upgraded to D from D- on 3/6/2023 due to an increase in the volatility index and valuation index.
D
Sell
2/15/2023Downgrade
Appili Therapeutics Inc. (APLIF) was downgraded to D- from D on 2/15/2023 due to a decline in the volatility index, solvency index and valuation index. The quick ratio declined from 2.15 to 0.88, and debt to equity increased from -1.87 to -1.01.
Appili Therapeutics Inc. (APLIF) was downgraded to D- from D on 2/15/2023 due to a decline in the volatility index, solvency index and valuation index. The quick ratio declined from 2.15 to 0.88, and debt to equity increased from -1.87 to -1.01.
D
Sell
2/10/2023Upgraded
Appili Therapeutics Inc. (APLIF) was upgraded to D from E+ on 2/10/2023 due to an increase in the volatility index and total return index.
Appili Therapeutics Inc. (APLIF) was upgraded to D from E+ on 2/10/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
Appili Therapeutics Inc. (APLIF) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
Appili Therapeutics Inc. (APLIF) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
1/25/2023Downgrade
Appili Therapeutics Inc. (APLIF) was downgraded to D- from D on 1/25/2023 due to a decline in the volatility index.
Appili Therapeutics Inc. (APLIF) was downgraded to D- from D on 1/25/2023 due to a decline in the volatility index.
D
Sell
1/5/2023Upgraded
Appili Therapeutics Inc. (APLIF) was upgraded to D from D- on 1/5/2023 due to an increase in the volatility index.
Appili Therapeutics Inc. (APLIF) was upgraded to D from D- on 1/5/2023 due to an increase in the volatility index.
D
Sell
12/15/2022Downgrade
Appili Therapeutics Inc. (APLIF) was downgraded to D- from D on 12/15/2022 due to a decline in the volatility index.
Appili Therapeutics Inc. (APLIF) was downgraded to D- from D on 12/15/2022 due to a decline in the volatility index.
D
Sell
11/29/2022Upgraded
Appili Therapeutics Inc. (APLIF) was upgraded to D from D- on 11/29/2022 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.02 to -$0.0103, EBIT increased 43.4% from -$1.62M to -$915.4, and operating cash flow increased 38.74% from -$3.87M to -$2.37M.
Appili Therapeutics Inc. (APLIF) was upgraded to D from D- on 11/29/2022 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.02 to -$0.0103, EBIT increased 43.4% from -$1.62M to -$915.4, and operating cash flow increased 38.74% from -$3.87M to -$2.37M.
D
Sell
8/15/2022Upgraded
Appili Therapeutics Inc. (APLIF) was upgraded to D- from E+ on 8/15/2022 due to a substantial increase in the growth index and valuation index. Earnings per share increased from -$0.037 to -$0.02, and EBIT increased 16.17% from -$1.93M to -$1.62M.
Appili Therapeutics Inc. (APLIF) was upgraded to D- from E+ on 8/15/2022 due to a substantial increase in the growth index and valuation index. Earnings per share increased from -$0.037 to -$0.02, and EBIT increased 16.17% from -$1.93M to -$1.62M.
E
Sell
8/18/2021Downgrade
Appili Therapeutics Inc. (APLIF) was downgraded to E+ from D- on 8/18/2021 due to a large decline in the growth index, volatility index and total return index. Operating cash flow declined 60.79% from -$3.43M to -$5.51M, earnings per share declined from -$0.0629 to -$0.0955, and EBIT declined 40.17% from -$4.42M to -$6.2M.
Appili Therapeutics Inc. (APLIF) was downgraded to E+ from D- on 8/18/2021 due to a large decline in the growth index, volatility index and total return index. Operating cash flow declined 60.79% from -$3.43M to -$5.51M, earnings per share declined from -$0.0629 to -$0.0955, and EBIT declined 40.17% from -$4.42M to -$6.2M.
D
Sell
2/1/2021Upgraded
Appili Therapeutics Inc. (APLIF) was upgraded to D- from E on 2/1/2021 due to an increase in the growth index and valuation index. Earnings per share increased from -$0.0374 to -$0.0302.
Appili Therapeutics Inc. (APLIF) was upgraded to D- from E on 2/1/2021 due to an increase in the growth index and valuation index. Earnings per share increased from -$0.0374 to -$0.0302.
E
Sell
11/2/2020Upgraded
Appili Therapeutics Inc. (APLIF) was upgraded to E from E- on 11/2/2020 due to a noticeable increase in the volatility index, total return index and valuation index.
Appili Therapeutics Inc. (APLIF) was upgraded to E from E- on 11/2/2020 due to a noticeable increase in the volatility index, total return index and valuation index.
E
Sell
8/13/2020None
Appili Therapeutics Inc. (APLIF) was downgraded to E- from U on 08/13/2020.
Appili Therapeutics Inc. (APLIF) was downgraded to E- from U on 08/13/2020.
OTC PK
04/16/2024 9:54AM Eastern
Quotes delayed
